electroCore

ECOR

Market cap $62.1M

ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of symptoms associated with PTSD.

ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today provided select unaudited preliminary financial guidance for the full year and fourth quarter of 2025.

electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript

ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025.

ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.

electroCore, Inc. ( ECOR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Daniel Goldberger - CEO & Director Thomas Errico - Founder & Independent Chairman Joshua Lev - Chief Financial Officer Conference Call Participants Rob Fink - FNK IR LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Walter Schenker - MAZ Capital Advisors, LLC Presentation Rob Fink FNK IR LLC Greetings, everyone, and welcome to the electroCore Third Quarter 2025 Earnings Conference Call.

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.31 per share a year ago.

Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024

electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025.